Sifalimumab

Drug Profile

Sifalimumab

Alternative Names: Anti-IFNa MAb; MDX-1103; MEDI-545

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Medarex
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myositis; Psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 19 Jul 2016 MedImmune completes its phase II trial for Systemic lupus erythematosus in Japan (NCT01031836)
  • 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA and Japan (SC)
  • 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, France, Germany, Hungary, India, Italy, Jamaica, Japan, Mexico, Netherlands, Peru, Philippines, Poland, Romania, South Africa, Spain, Thailand and United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top